

Attorney Docket No. AP32556-071838.0125  
PATENT

**CLAIM AMENDMENTS**

Please cancel Claims 51 and 66 without prejudice.

Please amend the claims as follows:

1-44. (Canceled)

45. (Currently Amended) A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin with an effective amount of a nucleic acid molecule selected from the group consisting of 5'-~~ATCTCTCGGCTTCCTTTC~~ 3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification, and wherein the nucleic acid molecule or modified nucleic acid molecule is capable of reducing the level of IGF-I receptor in said mammal.

46. (Previously Amended) The method according to Claim 45 wherein the mammal is a human.

47-48. (Canceled)

Attorney Docket No. AP32556-071838.0125  
PATENT

49. (Previously Amended) The method according to Claim 45 wherein the proliferative or inflammatory skin disorder is psoriasis, eczema, ichthyosis, pityriasis, rubra, pilaris, seborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.
50. (Currently Amended) The method according to Claim 49 wherein the ~~skin condition~~ disorder is psoriasis.
51. (Canceled)
52. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or a modification thereof.
53. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or a modification thereof.
54. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) or a modification thereof.
55. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) or a modification thereof.
56. (Previously Amended) The method according to Claim 45 herein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or a modification thereof.
57. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or a modification thereof.
58. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or a modification thereof.

Attorney Docket No. AP32556-071838.0125  
PATENT

59. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or a modification thereof.
60. (Previously Amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or a modification thereof.
- 61-63. (Canceled)
64. (Currently Amended) A method of ameliorating the effects of psoriasis in a mammal, said method comprising contacting proliferating skin with an effective amount of one or more nucleic acid molecules or selected from the group consisting of 5'-~~ATCTCTCCGCTTCGTTTC~~-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification and wherein said nucleic acid molecule or modified nucleic acid molecule is capable of interacting with mRNA transcribed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP.
65. (Previously Amended) The method according to Claim 64 wherein the mammal is a human.
66. (Canceled)

Attorney Docket No. AP32556-071838.0125  
PATENT

67. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or a modification thereof.
68. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or a modification thereof.
69. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) or a modification thereof.
70. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) or a modification thereof.
71. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or a modification thereof.
72. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UACAGAGGUCAGCA-3' (SEQ ID NO:17) or a modification thereof.
73. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or a modification thereof.
74. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or a modification thereof.
75. (Previously Amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or a modification thereof.

Attorney Docket No. AP32556-071838.0125  
PATENT

76. (Currently Amended) A composition comprising a nucleic acid molecule selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification ~~and wherein said nucleic acid molecule or modified nucleic acid molecule~~, and wherein said nucleic acid molecule or modified nucleic acid molecule is capable of reducing the level of IGF-I receptor in a mammal said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.
77. (Previously Amended) The composition according to Claim 76 wherein the mammal is a human.
78. (Canceled)
79. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or a modification thereof.
80. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or a modification thereof.
81. (Canceled)

Attorney Docket No. AP32556-071838.0125  
PATENT

82. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) or a modification thereof.
83. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or a modification thereof.
84. (Previously Amended) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or a modification thereof.
85. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or a modification thereof.
86. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or a modification thereof.
87. (Previously Amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or a modification thereof.